Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products

Blood

Volumn 101, Issue 10, 2003, Pages 4195-4200

  Nichols, W Garrett ^a   Price, Thomas H ^b   Gooley, Ted ^b   Corey, Lawrence ^b   Boeckh, Michael ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ANTIGEN DETECTION; ARTICLE; ASSAY; BLOOD DONOR; BLOOD FILTRATION; BLOOD TRANSFUSION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; HEALTH SURVEY; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; SEROPREVALENCE; ALLOTRANSPLANTATION; BLOOD COMPONENT THERAPY; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE TRANSMISSION; FOLLOW UP; STEM CELL TRANSPLANTATION; TIME;

BLOOD COMPONENT TRANSFUSION; CYTOMEGALOVIRUS INFECTIONS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MULTIVARIATE ANALYSIS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0038603187     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3143     Document Type: Article

References (36)

1. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006-1010.
2. Miller WJ, McCullough J, Balfour HH, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991;7:227-234.
3. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr. 1981;98:281-287.
4. Stoddart CA, Cardin RD, Boname JM, Manning WC, Abenes GB, Mocarski ES. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J Virol. 1994;68:6243-6253.
5. Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest. 1997;100:3154-3163.
6. Preiksaitis JK. The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening? Transfusion Med Rev. 2000;14:112-136.
7. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598-3603.
8. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection [letter]. Blood. 1996;87:4910.
9. Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant. 1998;22:575-577.
10. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 1991;78:246-250.
11. De Witte T, Schattenberg A, Van Dijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation. 1990;50:964-968.
12. van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol. 1994;87:144-147.
13. Verdonck LF, de Graan-Hentzen YC, Dekker AW, Mudde GC, de Gast GC. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant. 1987;2:73-78.
14. Eisenfeld L, Silver H, McLaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion. 1992;32:205-209.
15. Buckner CD, Clift RA, Appelbaum FR, et al. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. Bone Marrow Transplant. 1991;7:6-8.
16. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036-2043.
17. Lynch MH, Petersen FB, Appelbaum FR, et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant. 1995;15:59-64.
18. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89:3880-3887.
19. Storb R, Leisenring W, Deeg HJ, et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood. 1994;83:2749-2750.
20. Landry ML, Ferguson D, Stevens-Ayers T, de Jonge MW, Boeckh M. Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence. J Clin Microbiol. 1996;34:1337-1339.
21. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood. 1999;93:1781-1782.
22. Boeckh M, Stevens-Ayers T, Bowden RA. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis. 1996;174:907-912.
23. American Association of Blood Banks. Association Bulletin #97-2. Leukocyte Reduction for the Prevention of Transfusion Transmitted Cytomegalovirus (TT-CMV). Bethesda, MD: April 23, 1997.
24. Ljungman P, Plotkin SA. Workshop on CMV disease: definitions, clinical severity scores, and new syndromes. Scand J Infect Dis. 1995;99: S87-S88.
25. Dumont LJ, Luka J, VandenBroeke T, Whitley P, Ambruso DR, Elfath MD. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood. 2001;97:3640-3647.
26. Butt NM, Clark RE. High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV. Bone Marrow Transplant. 2001;27:615-619.
27. Mori T, Okamoto S, Watanabe R, et al. Incidence of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell recipients at low risk of CMV infection. Bone Marrow Transplant. 2002;29:1005-1006.
28. Ljungman P, Larsson K, Kumlien G, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis. 2002;34:347-350.
29. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med. 2000;132:715-722.
30. Meryman HT, Bross J, Lebovitz R. The preparation of leukocyte-poor red blood cells: a comparative study. Transfusion. 1980;20:285-292.
31. Slichter SJ. Optimum platelet concentrate preparation and storage. In: Garratty G, ed. Current Concepts in Transfusion Therapy. Arlington, VA: American Association of Blood Banks; 1985:1-26.
32. Blajchman MA, Goldman M, Freedman JJ, Sher GD. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev. 2001;15:1-20.
33. Roback JD. CMV and blood transfusions. Rev Med Virol. 2002;12:211-219.
34. Associated Press. Donated blood needs filtering, panel advises. New York Times. January 28, 2001:19.
35. Sweeney JD. Universal leukoreduction of cellular blood components in 2001? Yes. Am J Clin Pathol. 2001;115:666-673.
36. Goodnough LT. Universal leukoreduction of cellular blood components in 2001? No. Am J Clin Pathol. 2001;115:674-677.